{"article_title": "Lupin Adds Gavin, Grows in U.S. Pharma Market", "article_keywords": ["pharmaceutical", "novel", "adds", "pharma", "generic", "lupin", "gavin", "jersey", "miralax", "products", "plan", "laboratories", "grows", "market"], "article_url": "http://www.themiddlemarket.com/news/healthcare/lupin-adds-gavin-grows-in-us-pharma-market-257405-1.html", "article_text": "Lupin Adds Gavin, Grows in U.S. Pharma Market\n\nGavin's pharmaceutical products include MiraLax and Plan B One-Step\n\nMumbai-based Pharma Major Lupin Ltd. plans to expand in the U.S. generic drug market by picking up Gavis Pharmaceuticals LLC and Novel Laboratories Inc. in an $880 million deal.\n\nGavis, headquartered in Somerset, New Jersey, formulates, markets and distributes pharmaceutical products, including generic versions of MiraLax and Plan B One-Step. Novel Laboratories Inc., which is part of Gavis, is a research and development business that commercializes medication.\n\nGavis has a manufacturing facility in New Jersey, which will be Lupin's first U.S. site.\n\nLupin develops branded and generic medications for cardiovascular, diabetes, asthma, pediatric, anti-infection and other uses.\n\nOther recent pharmaceutical deals include Cathay Capital Private Equity's investment in pharmaceutical development business Cenexi Group, and a CVC Capital Partners-led consortium's purchase of pharma company Alvogen.\n\nFor more information on related topics, visit the following:", "article_metadata": {"og": {"url": "http://www.themiddlemarket.com/news/healthcare/lupin-adds-gavin-grows-in-us-pharma-market-257405-1.html", "image": "http://cdn.themiddlemarket.com/media/newspics/gavi-lax.jpg", "site_name": "Mergers & Acquisitions, Latest News", "title": "Lupin Adds Gavin, Grows in U.S. Pharma Market"}}, "_id": "\"57477af46914bd0286fdfba0\"", "article_summary": "Lupin Adds Gavin, Grows in U.S. Pharma MarketGavin's pharmaceutical products include MiraLax and Plan B One-StepMumbai-based Pharma Major Lupin Ltd. plans to expand in the U.S. generic drug market by picking up Gavis Pharmaceuticals LLC and Novel Laboratories Inc. in an $880 million deal.\nNovel Laboratories Inc., which is part of Gavis, is a research and development business that commercializes medication.\nGavis, headquartered in Somerset, New Jersey, formulates, markets and distributes pharmaceutical products, including generic versions of MiraLax and Plan B One-Step.\nLupin develops branded and generic medications for cardiovascular, diabetes, asthma, pediatric, anti-infection and other uses.\nOther recent pharmaceutical deals include Cathay Capital Private Equity's investment in pharmaceutical development business Cenexi Group, and a CVC Capital Partners-led consortium's purchase of pharma company Alvogen."}